Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307259 | 0.85 | USP2 (0.36) | PAOXALDH1A1USP2ALOX15TSHR | |
| SCHEMBL18022588 | 0.79 | USP2 (0.32) | USP2ALOX15 | |
| SCHEMBL11440164 | 0.77 | USP2 (0.37) | USP2ALOX15TSHR | |
| SCHEMBL1307416 | 0.77 | ALDH1A1 (0.45) | PAOXALDH1A1USP2ALOX15TSHR | |
| SCHEMBL95945 | 0.77 | — | — | |
| SCHEMBL235041 | 0.76 | SIGMAR1 (0.42) | PAOXALDH1A1SLC2A1NPSR1SIGMAR1 | |
| SCHEMBL271219 | 0.75 | — | — | |
| SCHEMBL303288 | 0.73 | DNM1 (0.52) | TSHR | |
| SCHEMBL303397 | 0.73 | DNM1 (0.52) | TSHR | |
| SCHEMBL303801 | 0.73 | DNM1 (0.52) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | claimed |
| WO-2022006439-A2 | COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | disclosed |
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | PAOX 2158/4885ALDH1A1 2589/4885SLC2A1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.